9 July 2024 - Commercial product expected to be available by the end of July.
Arcutis Biotherapeutics today announced the US FDA has approved the supplemental new drug application for Zorvye (roflumilast) cream, 0.15%, for the treatment of mild to moderate atopic dermatitis in adult and paediatric patients 6 years of age and older.